<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gene test interpretation: &lt;i&gt;ACKR1 &lt;/i&gt;(Duffy blood group gene)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gene test interpretation:
       <i>
        ACKR1
       </i>
       (Duffy blood group gene)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gene test interpretation:
        <i>
         ACKR1
        </i>
        (Duffy blood group gene)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles T Quinn, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy Berliner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynne Uhl, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford M Takemoto, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3847872734">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <em>
          ACKR1
         </em>
         gene encodes the Duffy antigen receptor for chemokines (DARC), which is expressed on red blood cells (RBCs), endothelial cells, and other cell types.
        </p>
        <p>
         Genetic variation in
         <em>
          ACKR1
         </em>
         determines Duffy blood group status, which in turn impacts malaria resistance, hemolytic transfusion reactions, and hemolytic disease of the fetus and newborn (HDFN). Duffy antigen expression also affects baseline neutrophil counts.
        </p>
        <p>
         Testing of
         <em>
          ACKR1
         </em>
         may be performed as a component of a multi-gene panel for transfusion antigens ("RBC genotyping") to guide transfusions and evaluate hemolytic transfusion reactions. Targeted testing of
         <em>
          ACKR1
         </em>
         , especially for the c.-67T&gt;C variant, may be performed to identify a genetic influence on baseline neutrophil counts. (See
         <a class="local">
          'Neutrophils (effect of Duffy status)'
         </a>
         below.)
        </p>
        <p>
         This monograph discusses clinical implications of
         <em>
          ACKR1
         </em>
         variants. Details of indications for testing and management are discussed separately [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'UpToDate topics'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H703984428">
         <span class="h1">
          BACKGROUND
         </span>
        </p>
        <p class="headingAnchor" id="H2137833465">
         <span class="h2">
          Terminology
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           ACKR1
          </em>
         </strong>
         <strong>
          and DARC
         </strong>
         –
         <em>
          ACKR1
         </em>
         (
         <a class="graphic graphic_figure graphicRef140094" href="/z/d/graphic/140094.html" rel="external">
          figure 1
         </a>
         ) encodes the atypical chemokine receptor 1, also called Duffy antigen receptor for chemokines (DARC).
         <em>
          DARC
         </em>
         was the former name of the
         <em>
          ACKR1
         </em>
         gene.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The DARC protein is a transmembrane receptor for chemoattractant cytokines (chemokines) of the CXC and CC families. (See
         <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">
          "Transplantation immunobiology", section on 'Chemokines and chemokine receptors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other names for the protein include Duffy blood group, Fy glycoprotein, and CD234.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duffy blood group antigens
         </strong>
         – Duffy (Fy) blood group antigens (Fy
         <sup>
          a
         </sup>
         and Fy
         <sup>
          b
         </sup>
         ) are genetically determined by a single nucleotide difference in the
         <em>
          ACKR1
         </em>
         coding region that changes a single amino acid.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fy
         <sup>
          a
         </sup>
         – Guanine at nucleotide 125 defines the
         <em>
          FY*A
         </em>
         haplotype, with glycine at amino acid 42.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fy
         <sup>
          b
         </sup>
         – Adenine at nucleotide 125 defines
         <em>
          FY*B
         </em>
         haplotype, with aspartate at amino acid 42.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duffy-null phenotype
         </strong>
         – Duffy-null, also called Fy(a−b−), is characterized by lack of Duffy antigens on red blood cells (RBCs). (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Duffy antigens'
         </a>
         .).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Duffy-null phenotype is caused by a variant in the
         <em>
          ACKR1
         </em>
         promoter that results in loss of expression of Duffy antigens on RBCs but does not affect expression on other cell types. (See
         <a class="local">
          'Expression of ACKR1/DARC'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          DANC
         </strong>
         – Duffy-null associated neutrophil count (DANC) is the normal range for neutrophil counts in individuals with Duffy-null RBCs. This is a genetically-determined baseline neutrophil count that is often lower than commonly-used laboratory reference ranges. This was formerly known as "benign ethnic neutropenia," but it is not a form of neutropenia or a risk factor for infection; rather, DANC represents normal human variation. (See
         <a class="local">
          'Reference ranges for Duffy-null and non-Duffy-null'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4139590827">
         <span class="h2">
          Expression of
          <i>
           ACKR1
          </i>
          /DARC
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RBCs
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duffy blood group
         </strong>
         – The variants that determine Fy
         <sup>
          a
         </sup>
         and Fy
         <sup>
          b
         </sup>
         are autosomal co-dominant. (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Duffy antigens'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Presence of the variant at one allele is sufficient to confer the presence of that Duffy antigen. There are four main RBC phenotypes:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fy(a+b+)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fy(a+b−)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fy(a−b+)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fy(a−b−), also called Duffy-null
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duffy-null
         </strong>
         – The presence or absence of Duffy antigens on RBCs depends on erythroid-specific transcription of
         <em>
          ACKR1
         </em>
         . Absence of Duffy antigens (Duffy-null) results from homozygosity for the
         <em>
          ACKR1
         </em>
         promotor variant rs2814778-C, which contains cytosine instead of thymine at position –67 (also designated –46, depending on the numbering system), which prevents binding of the GATA1 transcription factor  (
         <a class="graphic graphic_figure graphicRef140094" href="/z/d/graphic/140094.html" rel="external">
          figure 1
         </a>
         ) in RBC precursors [
         <a href="#rid2">
          2
         </a>
         ]. The variant is designated c.-67T&gt;C; homozygosity may be abbreviated C/C.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The c.-67T&gt;C promoter variant is commonly linked to the coding region variant
         <em>
          FY*B
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ]. It prevents expression of the
         <em>
          FY*B
         </em>
         allele and is sometimes called
         <em>
          FY*B
         </em>
         <em>
          <sup>
           ES
          </sup>
         </em>
         for "erythrocyte silent." The variant can rarely be associated with
         <em>
          FY*A
         </em>
         (
         <em>
          FY*A
         </em>
         <em>
          <sup>
           ES
          </sup>
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Duffy-null status is autosomal recessive. Only individuals who are homozygous for the c.-67T&gt;C variant are Duffy-null. Other rare
         <em>
          ACKR1
         </em>
         variants can also cause the Duffy-null phenotype but do not affect neutrophil count [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutrophils
         </strong>
         – DARC (and Duffy antigens) are not expressed on neutrophils. However, the presence or absence of Duffy antigens on RBCs affects the baseline neutrophil count. (See
         <a class="local">
          'Neutrophils (effect of Duffy status)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endothelial and epithelial cells
         </strong>
         – DARC is expressed on endothelial cells (capillary and postcapillary venules), epithelial cells (kidneys, collecting ducts, and lung alveoli), and Purkinje cells in the cerebellum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Homozygosity for c.-67T&gt;C does not affect expression
         <em>
          of FY*B
         </em>
         in non-RBC cell types. This is why Duffy-null individuals generally do not develop anti-Fy
         <sup>
          b
         </sup>
         [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H749700871">
         <span class="h2">
          Geographic variation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Geographic mapping has been used to determine the distribution of
         <em>
          ACKR1
         </em>
         alleles. The most common alleles in contemporary populations are [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sub-Saharan Africa
         </strong>
         –
         <em>
          FY*B
         </em>
         <em>
          <sup>
           ES
          </sup>
         </em>
         <em>
          /FY*B
         </em>
         <em>
          <sup>
           ES
          </sup>
         </em>
         (producing the Duffy-null phenotype) in &gt;95 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Americas
         </strong>
         –
         <em>
          FY*A/FY*B
         </em>
         in 31 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Europe
         </strong>
         –
         <em>
          FY*A/FY*B
         </em>
         in 52 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asia
         </strong>
         –
         <em>
          FY*A/FY*A
         </em>
         in &gt;80 percent
        </p>
        <p>
        </p>
        <p>
         Worldwide distribution of the Duffy-null phenotype is illustrated in the figure  (
         <a class="graphic graphic_figure graphicRef141360" href="/z/d/graphic/141360.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1831557415">
         <span class="h1">
          CLINICAL IMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H143015741">
         <span class="h2">
          How to read the genetic test report
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with all genetic testing, confirm the correct person was tested, determine which gene(s) were evaluated, and verify that the test was performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or other nationally certified laboratory. These principles are summarized in the table  (
         <a class="graphic graphic_table graphicRef122437" href="/z/d/graphic/122437.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3558566937">
         <span class="h2">
          Duffy blood group antigens
         </span>
         <span class="headingEndMark">
          —
         </span>
         All red blood cells (RBCs) have surface antigens that determine blood type. When certain antigens are absent, exposure to these antigens via allogeneic blood (transfusion, pregnancy, sharing needles) can elicit an immune response. Alloantibodies against Duffy blood group antigens (anti-Fy) can cause clinically significant hemolysis  (
         <a class="graphic graphic_table graphicRef140075" href="/z/d/graphic/140075.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Genetic testing and RBC serologic testing are considered comparable for determining Duffy antigen status for transfusion practice. Most transfusion medicine services will use serologic testing, although the genotype may be helpful in certain settings such as recent transfusion.
        </p>
        <p class="headingAnchor" id="H2752374243">
         <span class="h3">
          Hemolytic transfusion reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemolytic transfusion reactions can occur when an individual has an alloantibody against Fy
         <sup>
          a
         </sup>
         or Fy
         <sup>
          b
         </sup>
         and is transfused with RBCs that express that antigen. (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who are Fy(a+b–) can make anti-Fy
         <sup>
          b
         </sup>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who are Fy(a-b+) can make anti-Fy
         <sup>
          a
         </sup>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who are Fy(a+b+) do not make anti-Fy
         <sup>
          a
         </sup>
         or anti-Fy
         <sup>
          b
         </sup>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals who are Duffy-null typically can make anti-Fy
         <sup>
          a
         </sup>
         but not anti-Fy
         <sup>
          b
         </sup>
         , because they express the "b" antigen on other tissues. (See
         <a class="local">
          'Expression of ACKR1/DARC'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         Routine pretransfusion testing will identify alloantibodies to Duffy antigens. If transfusion is needed, antigen-negative units will be provided. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Antibody screen'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1110159353">
         <span class="h3">
          Hemolytic disease of the fetus and newborn (HDFN)
         </span>
         <span class="headingEndMark">
          —
         </span>
         If fetal RBCs express antigens inherited from the father that are recognized by the maternal immune system as foreign, alloimmunization can occur, and alloantibodies can cross the placenta and cause hemolysis in the fetus and newborn.
        </p>
        <p>
         Anti-Fy
         <sup>
          a
         </sup>
         can be associated with HDFN. During pregnancy, a maternal antibody screen that identifies anti-Fy
         <sup>
          a
         </sup>
         will prompt testing of the father and enhanced monitoring for HDFN if appropriate. (See
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy", section on 'Duffy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy", section on 'Antibody screening'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3022272053">
         <span class="h2">
          Malaria risk
         </span>
         <span class="headingEndMark">
          —
         </span>
         Duffy antigen receptor for chemokines (DARC) serves as the only receptor on RBCs for
         <em>
          Plasmodium vivax
         </em>
         and the less common
         <em>
          P. knowlesi
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ]. Duffy-null individuals are protected from infection with these malarial species
         <em>
          . P vivax
         </em>
         and
         <em>
          P knowlesi
         </em>
         merozoites can attach to Fy(a–/b–) RBCs, but they cannot enter the RBC and eventually detach, leaving the cell markedly deformed. Risk for other malaria species is not affected. (See
         <a class="medical medical_review" href="/z/d/html/5703.html" rel="external">
          "Pathogenesis of malaria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7099.html" rel="external">
          "Protection against malaria by variants in red blood cell (RBC) genes", section on 'Duffy blood group system'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3076541999">
         <span class="h2">
          Neutrophils (effect of Duffy status)
         </span>
        </p>
        <p class="headingAnchor" id="H1415428978">
         <span class="h3">
          Absolute neutrophil count (ANC)
         </span>
         <span class="headingEndMark">
          —
         </span>
         An individual's Duffy status (Duffy-null versus non-Duffy-null) affects the reference ranges for baseline neutrophil counts. Duffy-null status is a normal variant. It is not a disease, and it does not cause any clinical disorder  (
         <a class="graphic graphic_table graphicRef140075" href="/z/d/graphic/140075.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         The ANC is an absolute number of mature neutrophils and band forms per unit of blood and thus a more accurate measure of the quantity of circulating neutrophils than the percentage of neutrophils.
        </p>
        <p>
         The mechanism by which Duffy status determines the normal range for the ANC remains unclear. Hypotheses include a role for RBC DARC as a sink for circulating chemokines, alterations in precursor cell differentiation in the bone marrow, and increased trafficking of neutrophils to other compartments (spleen, bone marrow, vasculature, or other tissues) in Duffy-null individuals [
         <a href="#rid2">
          2,4,5
         </a>
         ]. DARC is not expressed on neutrophils. (See
         <a class="local">
          'Expression of ACKR1/DARC'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2376261175">
         <span class="h3">
          Reference ranges for Duffy-null and non-Duffy-null
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reference ranges for ANC differ for individuals with Duffy-null and non-Duffy-null phenotypes (reference ranges also differ for children and adults). Duffy-null-associated neutrophil count (DANC) refers to the ANC in individuals who are homozygous for the c.-67T&gt;C promotor variant in
         <em>
          ACKR1
         </em>
         . (See
         <a class="local">
          'Expression of ACKR1/DARC'
         </a>
         above.)
        </p>
        <p>
         If there is a question regarding the reference range for a particular individual, Duffy-null status can be ascertained by genotyping (preferred) or by RBC phenotyping using serologic testing. Serologic RBC phenotyping may have an important limitation in identifying DANC, as RBCs may type as Duffy-null if they are Fy(a–b–) or if they carry the rare variant Fy
         <sup>
          x
         </sup>
         , which is not associated with DANC [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Geographic ancestry may be a reasonable marker of increased likelihood of a certain genotype (see
         <a class="local">
          'Geographic variation'
         </a>
         above), but race should not be used as a proxy for biological differences in neutrophil count [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">
          "Overview of neutropenia in children and adolescents", section on 'Normal variants'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia", section on 'Normal variants &lt;1500/microL'
         </a>
         .)
        </p>
        <p>
         In a study of 120 individuals who self-identified as Black or African American seen for routine, nonurgent outpatient visits, 80 (67 percent) were Duffy-null and 40 (33 percent) were non-Duffy-null [
         <a href="#rid9">
          9
         </a>
         ]. ANCs in the two groups were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duffy-null
         </strong>
         – Median ANC 2820/microL, range 1080 to 5950/microL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Non-Duffy-null
         </strong>
         – Median ANC 5005/microL, range 2360 to 10,500/microL
        </p>
        <p>
        </p>
        <p>
         Nearly one-fourth of Duffy-null individuals had an ANC below the lower limit of published reference intervals; one-tenth had an ANC &lt;1500/microL, which despite being a normal variant in these participants could be designated as neutropenia and could lead to unnecessary bone marrow examinations and inappropriate dose reduction or withholding of important medications. (See
         <a class="local">
          'Drug dosing'
         </a>
         below.)
        </p>
        <p>
         A larger study reported similar findings, with an ANC &lt;1000/microL in &gt;5 percent of individuals with DANC [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4024877752">
         <span class="h3">
          Risk of infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         DARC has no impact on response to bacterial or common viral infections [
         <a href="#rid11">
          11
         </a>
         ]. People with DANC have normal bone marrow cellularity and a robust neutrophil response to infection [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Duffy-null individuals have resistance to
         <em>
          P vivax
         </em>
         and
         <em>
          P knowlesi
         </em>
         malaria. (See
         <a class="local">
          'Malaria risk'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Some studies have suggested that Duffy-null individuals have an increased risk of HIV infection; others have suggested they have a survival advantage with HIV [
         <a href="#rid2">
          2,12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3539985467">
         <span class="h3">
          Drug dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         One concern for individuals with DANC is that they will receive dose reductions or have doses held for important drugs based on their lower baseline neutrophil count; this may include critical medications for inflammatory conditions, sickle cell disease, and cancer.
        </p>
        <p>
         It is important to consider the possibility of DANC and to avoid inadvertently withholding or underdosing medications, a practice that affects predominantly people with African ancestry [
         <a href="#rid13">
          13
         </a>
         ]. Genotyping or phenotyping for DANC can reduce racial disparities in health care. (See
         <a class="medical medical_review" href="/z/d/html/2904.html" rel="external">
          "Overview of pharmacogenomics", section on 'Potential benefits of genotyping'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2579471093">
         <span class="h2">
          First-degree relatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         First-degree relatives of the tested individual may benefit from knowing their
         <em>
          ACKR1
         </em>
         genotype or Duffy antigen status for purposes of determining whether their ANC is in the normal range and in determining the likelihood of HDFN during pregnancy. (See
         <a class="local">
          'Clinical implications'
         </a>
         above.)
        </p>
        <p>
         Consultation with experts in genetics, hematology, or transfusion medicine may be helpful. (See
         <a class="local">
          'Listings of experts'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3705427889">
         <span class="h1">
          RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H2632578028">
         <span class="h2">
          UpToDate topics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duffy antigen
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7924.html" rel="external">
          "Red blood cell antigens and antibodies", section on 'Duffy blood group system'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neutrophil count
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/8375.html" rel="external">
          "Overview of neutropenia in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90654.html" rel="external">
          "Approach to the adult with unexplained neutropenia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion reactions
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7932.html" rel="external">
          "Hemolytic transfusion reactions"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemolytic disease of the fetus and newborn
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7921.html" rel="external">
          "Management of non-RhD red blood cell alloantibodies during pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2309734166">
         <span class="h2">
          Listings of experts
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic counselors
         </strong>
         – National Society of Genetic Counselors (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ffindageneticcounselor.nsgc.org%2F%3Freload%3Dtimezone&amp;token=AU2cQkyAZolWVu502Wzur%2F2gjdsB%2FYlqRYYyoKtNflzQ%2BZ4POBsSFXQiuwJDn5pefBPIAES8nVSzeVi4Tr3mXQ%3D%3D&amp;TOPIC_ID=139725" target="_blank">
          NSGC
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical geneticists
         </strong>
         – American College of Medical Genetics and Genomics (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinics.acmg.net%2F&amp;token=nbsXe3i4qfUea5RCPRHtOdEP95SDL7NSm8b1jbZpdwjlW9H1hfmmq%2FTbAbE64qhV&amp;TOPIC_ID=139725" target="_blank">
          ACMG
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologists
         </strong>
         – American Society of Hematology (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hematology.org%2Feducation%2Fpatients%2Ffind-a-hematologist&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2e0eQcf%2FZA%2BSjIcMsro0GwdobI27IX0ZlhTssJ%2BPipw41wNe29hTaZoTmPE%2BbGpPTK8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=139725" target="_blank">
          ASH
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion medicine
         </strong>
         – Association for the Advancement of Blood &amp; Biotherapies (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aabb.org%2F&amp;token=IQxLzDq4doJGUgaZgeIY0%2FfQ7CUz88aBOsAyp3f4mHM%3D&amp;TOPIC_ID=139725" target="_blank">
          AABB
         </a>
         )
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palmblad J, Höglund P. Ethnic benign neutropenia: A phenomenon finds an explanation. Pediatr Blood Cancer 2018; 65:e27361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howes RE, Patil AP, Piel FB, et al. The global distribution of the Duffy blood group. Nat Commun 2011; 2:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girbl T, Lenn T, Perez L, et al. Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis. Immunity 2018; 49:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles BA, Hsieh MM, Adeyemo AA, et al. Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia. PLoS One 2018; 13:e0194400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meny GM. An update on the Duffy blood group system. Immunohematology 2019; 35:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merz LE, Achebe M. When non-Whiteness becomes a condition. Blood 2021; 137:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weyand AC, McGann PT. Eliminating race-based reference ranges in haematology: a call to action. Lancet Haematol 2021; 8:e462.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merz LE, Story CM, Osei MA, et al. Absolute neutrophil count by Duffy status among healthy Black and African American adults. Blood Adv 2023; 7:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bagheri M, Chung CP, Dickson AL, et al. White blood cell ranges and frequency of neutropenia by Duffy genotype status. Blood Adv 2023; 7:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Legge SE, Christensen RH, Petersen L, et al. The Duffy-null genotype and risk of infection. Hum Mol Genet 2020; 29:3341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsuran V, Kulkarni H, He W, et al. Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. Clin Infect Dis 2011; 52:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sirugo G, Wonkam A. Beyond Race: A Wake-up Call for Drug Therapy Informed by Genotyping. Ann Intern Med 2022; 175:1187.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 139725 Version 5.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Supporting references are provided in the associated UpToDate topics, with selected citation(s) below.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30117263" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Ethnic benign neutropenia: A phenomenon finds an explanation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21468018" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The global distribution of the Duffy blood group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30446388" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Distinct Compartmentalization of the Chemokines CXCL1 and CXCL2 and the Atypical Receptor ACKR1 Determine Discrete Stages of Neutrophil Diapedesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29596498" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30908072" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : An update on the Duffy blood group system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33181819" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : When non-Whiteness becomes a condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34048684" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Eliminating race-based reference ranges in haematology: a call to action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35994632" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Absolute neutrophil count by Duffy status among healthy Black and African American adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35895516" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : White blood cell ranges and frequency of neutropenia by Duffy genotype status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32959868" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The Duffy-null genotype and risk of infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21507922" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35724383" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Beyond Race: A Wake-up Call for Drug Therapy Informed by Genotyping.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
